Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Evidence-based research underscores the importance of breastfeeding for the healthy development of late preterm infants, yet significant challenges can impede its success. This is a groundbreaking, problem-solving guide to the most effective techniques for breastfeeding this vulnerable population. Written for lactation consultants, NICU nurses, obstetrical nurses, and nurse-midwives, the book offers clear, simple, evidence-based solutions to the distinct breastfeeding difficulties affecting late preterm infants. The guide describes the characteristics of late preterm infants and the physiologi

Breastfeeding. --- Infants --- Premature infants. --- Birth, Premature --- Infants (Premature) --- Preemies --- Preterm infants --- Newborn infants --- Birth weight, Low --- Baby care --- Infant care --- Breast feeding --- Nursing (Breastfeeding) --- Suckling --- Lactation --- Wet nurses --- Care. --- Care and hygiene --- Nutrition

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Optimizing outcomes for women in labour at the global_x000D__x000D_ level requires evidence-based guidance of health workers_x000D__x000D_ to improve care through appropriate patient selection and_x000D__x000D_ use of effective interventions. In this regard the World_x000D__x000D_ Health Organization (WHO) published recommendations_x000D__x000D_ for induction of labour in 2011. _x000D__x000D_ _x000D__x000D_ The goal of the present guideline is to consolidate the guidance for effective_x000D__x000D_ interventions that are needed to reduce the global burden_x000D__x000D_ of prolonged labour and its consequences. The primary_x000D__x000D_ target audience includes health professionals responsible_x000D__x000D_ for developing national and local health protocols and_x000D__x000D_ policies as well as obstetricians midwives nurses general_x000D__x000D_ medical practitioners managers of maternal and child_x000D__x000D_ health programmes and public health policy-makers in all_x000D__x000D_ settings.

Reproductive Physiological Phenomena --- Patient Care --- Obstetric Labor Complications --- Delivery, Obstetric --- Labor, Obstetric --- Infant Care --- Pregnancy Complications --- Pregnancy --- Child Care --- Reproductive and Urinary Physiological Phenomena --- Health Services --- Therapeutics --- Obstetric Surgical Procedures --- Reproduction --- Analytical, Diagnostic and Therapeutic Techniques and Equipment --- Surgical Procedures, Operative --- Phenomena and Processes --- Health Care Facilities, Manpower, and Services --- Female Urogenital Diseases and Pregnancy Complications --- Health Care --- Diseases --- Perinatal Care --- Labor Presentation --- Labor, Induced --- Dystocia --- Labor, Induced (Obstetrics) --- Regulation.

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

As the first book that specifically addresses pediatric formulations in the context of drug development, Pediatric Formulations: A Roadmap covers anatomy and physiology of children as well as the technical state of the art, gives hints about where to find inspiration, and provides a suitable background on the regulatory framework. Existing books on pediatric formulations mainly discuss compounding at the pharmacy. This is not a “how to formulate” textbook for pharmaceutical scientists; the subtitle “A Roadmap” indicates that we are on a path in largely unexplored territory. It is an attempt to equip the reader with necessary information on how to get started with the appropriate mindset. Among medicinal specialties, pediatrics is a young discipline. The potential dangers of medicine were often underestimated in earlier times. Cough suppressants labeled as “suitable for children and adults” a hundred years ago could kill children as they contained opioids. Since then, a complex framework has evolved, with physicians, pharmacists, drug development companies, generic companies, academic scientists, regulatory authorities, reimbursement organizations, patients and children’s parents as key players. The position of children in our society has changed dramatically during the last century. Children were protected against clinical trials, yet thanks to clinical trials, many more children with cancer survive today. The development of age-adjusted drug formulations is not only a technical challenge. For new drugs today, there are laws both in the United States and the European Union that compel the research-based pharmaceutical industry to also consider children during drug development. One of the major demands of authorities is the development of age-appropriate formulations. Daniel Bar-Shalom is an Associate Professor in Drug Delivery at The Faculty of Health and Medical Sciences, University of Copenhagen. He has a degree in Biology from The Tel-Aviv University (1975), carried research in botany and then graduated from the School of Pharmacy, Hebrew University of Jerusalem (1982). He is a qualified pharmacist and has managed and owned a pharmacy in Haifa where he gained insight into the needs and idiosyncrasies of patients. He moved to Denmark in 1986 and founded Egalet, a drug delivery company where he served until 2007 as Vice President, R&D. He has been a consultant for various pharmaceutical and medical device companies. He is also the inventor of various technologies, holds many patents and has formulated marketed products. His main interests are controlled drug delivery and in particular oral pediatric formulations and geriatric formulations addressing the problem of polypharmacy. Dr. Klaus Rose is CEO of Klausrose Consulting, Switzerland and advises on pediatric drug development and how to comply with FDA and EMA pediatric requirements. He has studied Latin languages, psychology and medicine. After postgraduate clinical training in general medicine in Germany and England, he joined the pharmaceutical industry. He has held various positions in R&D and medical affairs, was Global Head Pediatrics Novartis from 2001 to 2005 and was Global Head Pediatrics Roche from 2005 to 2009. After a year with a regulatory consultancy, he established his own business. Dr. Rose is a frequent speaker on international conferences on pediatric drug development, organizes trainings and publishes on a regular base.

Drugs -- Dosage forms. --- Infant care. --- Medicine -- Formulae, receipts, prescriptions. --- Newborn infants -- Effect of drugs on. --- Pediatric pharmacology. --- Pediatrics -- Formulae, receipts, prescriptions. --- Pediatrics --- Drug Discovery --- Chemicals and Drugs --- Drug Therapy --- Medicine --- Chemistry, Pharmaceutical --- Therapeutics --- Health Occupations --- Investigative Techniques --- Pharmacology --- Chemistry --- Analytical, Diagnostic and Therapeutic Techniques and Equipment --- Disciplines and Occupations --- Natural Science Disciplines --- Biological Science Disciplines --- Drug Delivery Systems --- Drug Design --- Pharmaceutical Preparations --- Health & Biological Sciences --- Pediatric pharmacology --- Drugs --- Drug development --- Biomedicine --- Testing --- Law and legislation --- Medicaments --- Medications --- Medicine (Drugs) --- Medicines (Drugs) --- Pharmaceuticals --- Prescription drugs --- Children --- Development of drugs --- New drug development --- Drug effects --- Effect of drugs on --- Development --- Medicine. --- Pharmacy. --- Pharmaceutical technology. --- Pediatrics. --- Biomedicine. --- Pharmaceutical Sciences/Technology. --- Pharmacy --- Bioactive compounds --- Medical supplies --- Pharmacopoeias --- Chemotherapy --- Materia medica --- Paediatrics --- Pediatric medicine --- Pharmaceutical laboratory techniques --- Pharmaceutical laboratory technology --- Technology, Pharmaceutical --- Technology --- Diseases --- Health and hygiene